CBAY stock forecast
Our latest prediction for CymaBay Therapeutics, Inc.'s stock price was made on the Oct. 10, 2019 when the stock price was at 4.31$.
In the short term (2weeks), CBAY's stock price should outperform the market by 6.04%. During that period the price should oscillate between -7.98% and +15.24%.
In the medium term (3months), CBAY's stock price should outperform the market by 5.52%. During that period the price should oscillate between -17.90% and +36.46%.Get email alerts
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.37$ per share.
The book value per share is 3.37$
Three months stock forecastOct. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|